Oxadiazole derivatives for inhibition of gamma secretase
Compounds of formula I: wherein X represents a 5-(R-substituted)-1,2,4-oxadiazole-3-yl moiety are inhibitors of gamma-secretase, and hence useful for treating Alzheimer's disease
1. A compound of formula I:
wherein the moiety X—R is attached at one of the positions indicated by an asterisk;
X is a 5-(R-substituted)-1,2,4-oxadiazol-3-yl moiety; and
R is selected from:
(i) a non-aromatic hydrocarbon group of up to 10 carbon atoms, optionally substituted with halogen, CF 3 , CHF 2 , CN, OH, CO 2 H, C 2-6 acyl, C 1-4 alkoxy or C 1-4 alkoxycarbonyl;
(ii) a non-aromatic heterocyclic group comprising up to 7 ring atoms of which up to 3 are chosen from N, O and S and the remainder are carbon, bearing 0–3 substituents independently selected from oxo, halogen, CN, C 1-6 alkyl, OH, CF 3 , CHF 2 , CH 2 F, C 2-6 acyl, CO 2 H, C 1-4 alkoxy and C 1-4 alkoxycarbonyl; and
(iii) phenyl or 6-membered heteroaryl, either of which bears 0–3 substituents independently selected from halogen, CF 3 , CHF 2 , CH 2 F, NO 2 , CN, OCF 3 , C 1-6 alkyl and C 1-6 alkoxy; or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1 which is homochiral and is [6S,9R,11R]2′,3′,4′,5,5′,6,7,8,9,10-decahydro-2-(5-(R-substituted)-1,2,4-oxadiazol -3yl)-5′-(2,2,2-trifluoroethyl)spiro[6,9-methanobenzocyclooctene-11,3′-[1,2,5]thiadiazole]1′,1′-dioxide, or a pharmaceutically acceptable salt thereof.
3. A compound according to claim 1 or claim 2 wherein R represents phenyl or a 6-membered heteroaryl, either of which bears 0–3 substituents independently selected from halogen, CF 3 , CHF 2 , CH 2 F, NO 2 , CN, OCF 3 , C 1-6 alkyl and C 1-6 alkoxy.
4. A compound according to claim 3 wherein R is selected from monohalophenyl, dihalophenyl, pyridyl, monohalopyridyl and trifluoromethylpyridyl, wherein “halo” refers to fluoro or chloro.
5. A compound according to claim 1 or claim 2 wherein the moiety —X—R is selected from:
6. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.
7. A method of treatment of a subject suffering from or prone to Alzheimer's disease which comprises administering to that subject an effective amount of a compound according to claim 1 .